Efficacy and Safety of Dose Adjustment and Delayed Response to Ustekinumab in Moderate ‐ Severe Crohn's Disease Patients: Results from the IM‐UNITI Maintenance Study: 2016 ACG Presidential Poster Award: 663. (October 2016)